NCT02859961Phase 2, phase 3Completed

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

Study sponsor: CytoDyn, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-09-16Actual
Enrollment · participants562Actual
Source updated2026-03-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of participants who remain on PRO 140 monotherapy regimen at the end of week 48 without experiencing virologic failure. After: Measure: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure.

Actual enrollment increased by 6 participants

Before: 556 participants (actual). After: 562 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview